CDR‑Life, founded in 2017, is advancing a new generation of immuno-oncology therapies built on its proprietary M-gager® antibody technology that targets intracellular proteins presented on MHC. Its lead program, CDR404, is described as the first dual MAGE‑A4 T‑cell engager aimed at treating multiple solid tumor indications. The company intends to use its Series A proceeds to advance CDR404 toward a potential clinical proof‑of‑concept readout and to expand its pipeline leveraging the M-gager® platform. The founding team has prior experience developing marketed antibody drugs (including Beovu®) and completing major biotech transactions. CDR‑Life also has a strategic partnership with Boehringer Ingelheim to develop an antibody fragment‑based therapeutic for geographic atrophy. The company has established itself in Europe, where it says the environment is conducive to clinical development and innovation.

Total raised

$76M

Funding rounds

1

Latest round

Series A

Latest activity

Apr 2022